In 1152 adults with obesity and type 2 diabetes, weekly retatrutide 9 mg and 12 mg cut bodyweight by 16·8% and 18·8% at 80 weeks vs 5·1% with placebo (p<0·0001). GI effects were common; stopping for adverse events or death: 12% (9 mg), 8% (12 mg), 5% (placebo).
RCTn = 1,152
Bellido et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial